Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jan 19, 2021 12:48pm
87 Views
Post# 32327081

RE:RE:RE:RE:RE:RE:RE:New investors from the deal

RE:RE:RE:RE:RE:RE:RE:New investors from the deal

The biggest faults with the Offering is not the issue price ..... The BIGGEST  Faults are th e issue of warrants and   the Conversion Price .....This is outrageous
 


SPCEO1 wrote: Hey, they are looking to get rid of us anyway I think! So, it even makes sense for management to accomplish their goal of neutrllizing the impact of this board by diversifying the list of shareholders! And warrants don't get to vote at the AGM, so it also protects their position if we were to sell our common shares and hold the warrants. It is a win/win for everyone!  

Actually, I was not thinking about that possibility when I suggested it but, you are right, it could lead to exhausted holders selling it and playing it only via the warrants. Still, it is only fair that we would get the same deal the new shareholders got. Why should they have the option to sell and play it through the warrants when legacy shareholders cannot?
 

palinc2000 wrote: So about another 35 million new warrants which would give old time shareholders reason to sell their holdings  in the hope of participating  in any upside over the conversion  price .....
That would put a lid on the SP !!!!!




<< Previous
Bullboard Posts
Next >>